Therefore, “dual pathway synthetic lethality” simultaneously targeting PARP1 and RAD52 offers a promising and very aggressive therapeutic approach against HR-compromised tumors, allowing for more robust elimination of cancer cells and preventing the emergence of drug resistance. Here, RAD52 is linked to cancer.